Product Type
Condition
Binding
Collectible Attributes
Free Shipping
Seller Location
Seller Rating
Published by Springer, 2013
ISBN 10: 1461465427ISBN 13: 9781461465423
Seller: booksXpress, Bayonne, NJ, U.S.A.
Book
Soft Cover. Condition: new.
Published by Springer, 2013
ISBN 10: 1461465427ISBN 13: 9781461465423
Seller: Lucky's Textbooks, Dallas, TX, U.S.A.
Book
Condition: New.
Published by Springer, 2013
ISBN 10: 1461465427ISBN 13: 9781461465423
Seller: Ria Christie Collections, Uxbridge, United Kingdom
Book Print on Demand
Condition: New. PRINT ON DEMAND Book; New; Fast Shipping from the UK. No. book.
Published by Springer, 2013
ISBN 10: 1461465427ISBN 13: 9781461465423
Seller: Revaluation Books, Exeter, United Kingdom
Book
Paperback. Condition: Brand New. 2013 edition. 59 pages. 9.00x6.00x0.25 inches. In Stock.
Published by Springer-Verlag New York Inc., 2013
ISBN 10: 1461465427ISBN 13: 9781461465423
Seller: THE SAINT BOOKSTORE, Southport, United Kingdom
Book Print on Demand
Paperback / softback. Condition: New. This item is printed on demand. New copy - Usually dispatched within 5-9 working days.
Published by Springer New York Feb 2013, 2013
ISBN 10: 1461465427ISBN 13: 9781461465423
Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germany
Book Print on Demand
Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy. Precise identification of the mechanism leading to MHC class I defects will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy. 60 pp. Englisch.
Published by Springer 2013-02, 2013
ISBN 10: 1461465427ISBN 13: 9781461465423
Seller: Chiron Media, Wallingford, United Kingdom
Book
PF. Condition: New.
Published by Springer New York, 2013
ISBN 10: 1461465427ISBN 13: 9781461465423
Seller: AHA-BUCH GmbH, Einbeck, Germany
Book
Taschenbuch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy. Precise identification of the mechanism leading to MHC class I defects will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy.
Published by Springer New York, 2013
ISBN 10: 1461465427ISBN 13: 9781461465423
Seller: moluna, Greven, Germany
Book Print on Demand
Kartoniert / Broschiert. Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Discusses molecular mechanisms of total or partial loss of the MHC class I antigens in cancer cells Explains the role of MHC class I defects in cancer progression Shows the correlation of MHC class I altered phenotypes with resistance to Immunothera.
Published by Springer, 2013
ISBN 10: 1461465427ISBN 13: 9781461465423
Seller: dsmbooks, Liverpool, United Kingdom
Book
paperback. Condition: New. New. book.